NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.76 +0.01 (+1.33 %)
(As of 12/11/2018 04:00 PM ET)
Previous Close$0.75
Today's Range$0.73 - $0.77
52-Week Range$0.32 - $1.59
Volume452,980 shs
Average Volume1.02 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:MTNB
Previous Symbol
CUSIPN/A
Phone+1-908-4431860

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees15
Outstanding Shares112,390,000
Market Cap$0.00
OptionableNot Optionable

Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) issued its quarterly earnings data on Friday, August, 10th. The company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The company earned $0.09 million during the quarter. View Matinas BioPharma's Earnings History.

When is Matinas BioPharma's next earnings date?

Matinas BioPharma is scheduled to release their next quarterly earnings announcement on Monday, March 25th 2019. View Earnings Estimates for Matinas BioPharma.

What price target have analysts set for MTNB?

1 Wall Street analysts have issued 12-month price objectives for Matinas BioPharma's stock. Their forecasts range from $5.00 to $5.00. On average, they expect Matinas BioPharma's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 557.9% from the stock's current price. View Analyst Price Targets for Matinas BioPharma.

What is the consensus analysts' recommendation for Matinas BioPharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Matinas BioPharma.

Has Matinas BioPharma been receiving favorable news coverage?

News articles about MTNB stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Matinas BioPharma earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,652,644 shares, an increase of 32.8% from the October 31st total of 2,750,372 shares. Based on an average daily trading volume, of 3,752,254 shares, the days-to-cover ratio is presently 1.0 days. Currently, 4.8% of the company's stock are sold short. View Matinas BioPharma's Current Options Chain.

Who are some of Matinas BioPharma's key competitors?

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the folowing people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 44)
  • Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 71)
  • Dr. Theresa Matkovits, Chief Devel. Officer (Age 51)
  • Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain
  • Dr. Jenel Cobb, Director of Project Management

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include K.J. Harrison & Partners Inc (0.17%) and Renaissance Technologies LLC (0.14%). Company insiders that own Matinas BioPharma stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma.

Which institutional investors are buying Matinas BioPharma stock?

MTNB stock was purchased by a variety of institutional investors in the last quarter, including K.J. Harrison & Partners Inc and Renaissance Technologies LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma.

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.76.

What is Matinas BioPharma's official website?

The official website for Matinas BioPharma is http://www.matinasbiopharma.com/.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.


MarketBeat Community Rating for Matinas BioPharma (NYSEAMERICAN MTNB)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  267
MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Featured Article: LIBOR

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel